[{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Clinipace Worldwide","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"On Target Laboratories \/ Clinipace Worldwide","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Clinipace Worldwide"},{"orgOrder":0,"company":"University of California, Irvine","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"University of California, Irvine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Irvine \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"University of California, Irvine \/ On Target Laboratories"},{"orgOrder":0,"company":"Ann & Robert H Lurie Children's Hospital of Chicago","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"Ann & Robert H Lurie Children's Hospital of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Ann & Robert H Lurie Children's Hospital of Chicago \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Ann & Robert H Lurie Children's Hospital of Chicago \/ On Target Laboratories"},{"orgOrder":0,"company":"Indiana University","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indiana University \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Indiana University \/ On Target Laboratories"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"On Target Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"On Target Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"On Target Laboratories","sponsor":"John Waters","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase II","graph3":"On Target Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"On Target Laboratories \/ John Waters","highestDevelopmentStatusID":"8","companyTruncated":"On Target Laboratories \/ John Waters"},{"orgOrder":0,"company":"Cedars-Sinai","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"FOLR","graph1":"Oncology","graph2":"Phase I","graph3":"Cedars-Sinai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cedars-Sinai \/ On Target Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Cedars-Sinai \/ On Target Laboratories"}]

Find Clinical Drug Pipeline Developments & Deals for Pafolacianine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Gastrointestinal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 15, 2025

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : On Target Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Esophageal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 26, 2025

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : John Waters

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of California, Irvine

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          University of California, Irvine

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastrointestinal Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 19, 2024

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : On Target Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Indiana University

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Indiana University

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 30, 2024

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : On Target Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Ann & Robert H Lurie Children's Hospital of Chicago

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Ann & Robert H Lurie Children's Hospital of Chicago

                          Country arrow
                          Organic Process R&D
                          Not Confirmed

                          Details : Pafolacianine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteosarcoma.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 31, 2024

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : On Target Laboratories

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : Cytalux (pafolacianine) is an FDA-approved optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

                          Product Name : Cytalux

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 11, 2022

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lung Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 27, 2020

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Clinipace Worldwide

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 08, 2017

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Syneos Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lung Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 19, 2016

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Medelis

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Organic Process R&D
                          Not Confirmed
                          Organic Process R&D
                          Not Confirmed

                          Details : OTL38 is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ovarian Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 16, 2014

                          Lead Product(s) : Pafolacianine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Syneos Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank